Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 11,365 shares of the biopharmaceutical company’s stock, valued at approximately $510,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Juno Therapeutics by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock valued at $187,879,000 after acquiring an additional 131,864 shares during the last quarter. BlackRock Inc. lifted its position in Juno Therapeutics by 2.6% in the second quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock worth $128,357,000 after buying an additional 110,503 shares during the last quarter. State Street Corp lifted its position in Juno Therapeutics by 7.4% in the second quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock worth $96,742,000 after buying an additional 222,754 shares during the last quarter. Capital World Investors lifted its position in Juno Therapeutics by 13.8% in the second quarter. Capital World Investors now owns 2,425,000 shares of the biopharmaceutical company’s stock worth $72,483,000 after buying an additional 295,000 shares during the last quarter. Finally, Redmile Group LLC bought a new stake in Juno Therapeutics in the second quarter worth $66,344,000. Hedge funds and other institutional investors own 70.37% of the company’s stock.
In other news, General Counsel Bernard J. Cassidy sold 28,000 shares of the firm’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $44.92, for a total transaction of $1,257,760.00. Following the transaction, the general counsel now owns 55,970 shares in the company, valued at $2,514,172.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richard Klausner sold 12,000 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $42.66, for a total value of $511,920.00. Following the transaction, the director now owns 783,536 shares in the company, valued at approximately $33,425,645.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 66,801 shares of company stock worth $3,039,661. Insiders own 15.08% of the company’s stock.
Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business’s revenue for the quarter was up 115.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.57) earnings per share. equities analysts predict that Juno Therapeutics, Inc. will post -4.02 earnings per share for the current year.
A number of analysts recently issued reports on the company. Wells Fargo & Company restated an “outperform” rating and issued a $54.00 price target (up from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th. Maxim Group restated a “buy” rating and issued a $56.00 price target on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Goldman Sachs Group restated a “neutral” rating and issued a $44.00 price target on shares of Juno Therapeutics in a research report on Friday, October 6th. Citigroup restated a “buy” rating and issued a $59.00 price target on shares of Juno Therapeutics in a research report on Tuesday, October 31st. Finally, Wedbush upgraded Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 price target for the company in a research report on Tuesday, August 29th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $45.48.
COPYRIGHT VIOLATION NOTICE: This report was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/12/06/raymond-james-financial-services-advisors-inc-invests-510000-in-juno-therapeutics-inc-juno-stock.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.